ETF-Investor

GILD Gilead Sciences

$166.53-1.45%2026-11-19 · Quote reference; see timestamp

01Recent performance

PeriodReturnHistorical percentile
Daily-1.45%Insufficient history
WTD—Insufficient history
MTD—Insufficient history
Period comparison through 2026-11-19
YTD—
From 52W high—
IV30—

Loading full research…

02How expensive is the company?

TTM PE N/M

Nonpositive earnings: PE percentile is not meaningful

Actual history 19.97Y · 222 month-end samples · 2006-11-30 — 2026-07-31

A comparison with its own history, not a standalone investment decision.

Valuation date 2026-11-19 · Futu market snapshot
Historical valuation chart
2002-03-282026-07-31

PB 15.84×

PB 15.84× · 99.58%
0%25%50%75%100%

Actual history 19.97Y · 240 month-end samples · 2006-11-30 — 2026-10-30

PB is affected by buybacks and equity structure; it is not a standalone trade signal.

Valuation date 2026-11-19 · Futu market snapshot
Historical valuation chart
1997-01-312026-10-30

03Earnings outlook

Forward PE31.69×
Expected EPS growth—

Forward PE · Futu · 2026-11-01

No verified comparable EPS growth forecast. Growth is not inferred from valuation ratios.

No verified comparable Forward PE history; no percentile scale is shown.

04ETFs holding the company

Loading full research…

05Peers & similar companies

Peers and similar companies first, followed by common stocks where needed.

Watch
AMGN——Business overlap————————
JNJ——Business overlap————————
MRK——Business overlap————————
PFE——Business overlap————————
ABBV——Similar business————————
BIIB——Similar business————————
LLY——Similar business————————
REGN——Similar business————————
UTHR——Similar business————————
VRTX——Similar business————————

Loading existing stock data…

Percentiles use each company’s own history; actual years appear beside values. Missing data is shown as —. Quote and valuation dates may differ; hover over values for available dates.

06Understand the company

The business in one sentence
Develops and sells medicines including antiviral and oncology treatments.

How it earns money
Sells HIV and other antiviral therapies, oncology products and other medicines across different patent cycles.

Why customers choose it · Research perspective
HIV regimens compete on resistance, safety and convenience, while oncology needs separate evidence by population.

What to watch next · Research perspective
Track HIV volumes and pricing, oncology sales and key trial results to distinguish core and new growth.

Sources

Gilead Sciences · SEC filings index

Futu · Gilead Sciences company profile

Sources checked

For research, not personal investment advice.

PASSWORD-FREE ACCESS

Continue with email

We’ll send you a secure sign-in link. No password required.

By continuing, you agree to the Terms and acknowledge the Privacy Policy.